We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-8.33%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$58.2M
Cap. Flow
-$26.3M
Cap. Flow %
-11.97%
Top 10 Hldgs %
60.72%
Holding
71
New
8
Increased
9
Reduced
20
Closed
15

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$8.71M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$8.07M
3
PTCT icon
PTC Therapeutics
PTCT
+$7.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.64M
5
LLY icon
Eli Lilly
LLY
+$2.75M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.8M
2
STML
Stemline Therapeutics, Inc.
STML
+$10.3M
3
ILMN icon
Illumina
ILMN
+$8.32M
4
GILD icon
Gilead Sciences
GILD
+$3.87M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$16.4B
$1.55M 0.71%
13,800
– –
TPTX
27
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.54M 0.7%
35,000
– –
STRO icon
28
Sutro Biopharma
STRO
$353M
$1.38M 0.63%
13,933
– –
PRNB
29
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$1.35M 0.62%
+23,100
New +$1.35M
QURE icon
30
uniQure
QURE
$3.44B
$1.29M 0.59%
27,500
+14,000
+104% +$804K
AMRN
31
Amarin Corp
AMRN
$297M
$1.27M 0.58%
16,000
-3,400
-18% -$1.13M
NKTR icon
32
Nektar Therapeutics
NKTR
$2.55B
$1.19M 0.54%
4,467
-4,866
-52% -$1.51M
SAGE
33
DELISTED
Sage Therapeutics
SAGE
$1.08M 0.49%
37,600
-3,800
-9% -$220K
IMMU
34
DELISTED
Immunomedics Inc
IMMU
$970K 0.44%
+72,000
New +$1.21M
TPST icon
35
Tempest Therapeutics
TPST
$17.9M
$939K 0.43%
912
– –
CRSP icon
36
CRISPR Therapeutics
CRSP
$5.74B
$930K 0.42%
22,000
– –
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$893K 0.41%
10,200
– –
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
$873K 0.4%
94,600
– –
AGIO icon
39
Agios Pharmaceuticals
AGIO
$2.05B
$762K 0.35%
21,500
-15,000
-41% -$693K
ALKS icon
40
Alkermes
ALKS
$8.2B
$749K 0.34%
+52,000
New +$928K
MYOK
41
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$743K 0.34%
15,859
-14,141
-47% -$906K
MNTA
42
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$734K 0.33%
27,000
-53,000
-66% -$1.48M
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$700K 0.32%
12,000
-5,000
-29% -$322K
DCPH
44
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$697K 0.32%
17,000
– –
ALLK
45
DELISTED
Allakos
ALLK
$692K 0.32%
+15,700
New +$1.07M
ARNA
46
DELISTED
Arena Pharmaceuticals Inc
ARNA
$690K 0.31%
16,500
– –
KYNB
47
Kyntra Bio
KYNB
$32.4M
$684K 0.31%
788
– –
TCDA
48
DELISTED
Tricida, Inc. Common Stock
TCDA
$635K 0.29%
29,000
-8,000
-22% -$257K
EXAS
49
DELISTED
Exact Sciences
EXAS
$619K 0.28%
10,700
– –
INSM icon
50
Insmed
INSM
$26.5B
$537K 0.24%
33,600
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2020 Portfolio in Review

As of Q1 2020, International Biotechnology Trust held 71 positions worth $219M, down 21% from $278M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

International Biotechnology Trust withdrew a net $26.3M in Q1 2020, closing 15 positions and reducing 20 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $10.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in ChemoCentryx, Inc. worth $7.63M.

  • International Biotechnology Trust's largest Q1 2020 buy was ChemoCentryx, Inc.: 190,000 shares worth $7.63M.
  • International Biotechnology Trust added most to Zogenix, Inc. in Q1 2020, an estimated $8.71M increase.
  • International Biotechnology Trust's biggest Q1 2020 reduction was Gilead Sciences, cutting an estimated $3.87M.
  • International Biotechnology Trust fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $10.8M.
  • International Biotechnology Trust's ten largest holdings make up 61% of its $219M portfolio in Q1 2020.
  • International Biotechnology Trust opened 8 new positions and closed 15 in Q1 2020.
  • International Biotechnology Trust's portfolio value fell 21% quarter-over-quarter to $219M.

Based on International Biotechnology Trust's 13F filing for Q1 2020, filed 18 May 2020.